

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/028,258	12/19/2001	Celal Albayrak	0081.02 2329		
33072	7590 07/31/2006	•	EXAMINER		
	INDER, PLLC	WANG, SHENGJUN			
•	MAPLE ISLAND BUIL STREET NORTH	ART UNIT	PAPER NUMBER		
STILLWAT	ER, MN 55082	1617			
			DATE MAILED: 07/31/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)				
Office Action Summary		10/028,258		ALBAYRAK, CELAL				
		Examiner		Art Unit				
	•			1617				
	The MAILING DATE of this communication	Shengjun Wang			dress			
Period fo								
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING ansions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory per re to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	COMPANTE OF THIS COMPANTED THIS COMP	MUNICATION. may a reply be timely 6) MONTHS from the ome ABANDONED	y filed e mailing date of this α (35 U.S.C. § 133).				
Status								
1)⊠	Responsive to communication(s) filed on 18	8 May 2006						
	This action is FINAL . 2b) This action is non-final.							
<i>'</i> =	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims		·					
4)⊠	I)⊠ Claim(s) <u>1-6 and 8-29</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) <u>1-6 and 8-29</u> is/are allowed.							
-	Claim(s) is/are rejected.							
	Claim(s) are subject to restriction an	d/or election requiremen	ıt.					
Applicati	on Papers	·						
• •	The specification is objected to by the Exam	inor						
			nd to by the Ev	ominor				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
	ınder 35 U.S.C. § 119	Examinor. Note the diff	ioned Omoc A		0-102.			
	-	ion minute, and a 05 H 6	0.0.0440/->./	n (0				
	12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
a)l		onto hava haan saasiisa	1					
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
* 5	application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
	and attached detailed Office action for a	ist of the certified copies	onor received.					
Attachmen	(c)							
	e of References Cited (PTO-892)	A) 🗆 Inton	view Summary (P	TO-413\				
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Pape	er No(s)/Mail Date.	··				
	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/ r No(s)/Mail Date	08) 5) Notic 6) Othe		rmal Patent Application (PTO-152)				

Application/Control Number: 10/028,258 Page 2

Art Unit: 1617

DETAILED ACTION

Receipt of applicants' amendments and remarks submitted May 18, 2006 is acknowledged.

1. The terminal disclaimer filed on May 18, 2006 disclaiming the terminal portion of any patent granted on this application, which would extend beyond the expiration date of US Patent 6,899,898 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Specification Objections

2. The use of the trademarks such as Poloxamere, Poloxamine, and Resomer etc. (page 18 and examples) has been noted in this application. It should be capitalized wherever it appears and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Reasons For Allowance

3. Applicants' amendments and remarks submitted May 18, 2006 have been fully considered, and are found persuasive with respect to the rejections over Rossling et al.

Particularly, the claimed invention is solely directed to a process of making polymeric microcapsules, which requires the selection of the proper solvents so that the a suspension of the polymeric microcapsules is formed within one minute of mixing the surfactant phase and the drug phase. The solvent systems as here employed are distinct from those employed by Rossling. Rossling's method require vacuum for the removal of solvent and thereby forming the microcapsules.

Application/Control Number: 10/028,258

Art Unit: 1617

Response to the Remarks about trademark.

4. As stated above, the trademark has to be accompanied by the generic terminology. The specification provides no clear information as to what the chemical structures are under those trademarks. Note the owners of the trademarks do not have the obligation to maintain the trademarks, and/or to insure that the product under the trademark be the same over the time period of the patent life and beyond.

Page 3

5. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

Application/Control Number: 10/028,258

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SHENGJUN WANG

Shengjun Wang
Primary Examiner
Art Unit 1617

Page 4